Ilantide delays the progression of experimental autoimmune encephalomyelitis. Experimental autoimmune encephalomyelitis (EAE) was induced in 30 animals, from among which 22 developed clinical signs of EAE (12 from the control group and 10 from the group treated with Ilantide-t). Clinical signs were evaluated daily. All of the data were aligned according to the onset of clinical signs and are presented as mean ± SEM. When the animals were killed, their clinical scores on the day they were killed were maintained at all subsequent time points. **P < 0.01 and ***P < 0.001 (two-way repeated-measures analysis of variance followed by the Bonferroni post hoc test).